{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:11:28Z","timestamp":1779369088531,"version":"3.53.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Compliance with guidelines in the empirical treatment for community-acquired pneumonia (CAP) is very important to increase treatment success and reduce mortality. This study aimed to determine compliance with guideline recommendations for CAP and define the role of the clinical pharmacist (CP). Patients diagnosed with CAP were evaluated retrospectively between January 2018 and January 2020 and prospectively between February 2020 and February 2021. Compliance with guidelines was evaluated according to the local, national (Turkish Thoracic Society), and international (American Thoracic Society and Infectious Disease Society of America, European Society of Clinical Microbiology and Infectious Diseases) guidelines. A total of 751 patients (423 in the retrospective and 328 in the prospective period) were included. It was determined that the 30-day mortality and length of stay were higher in patients who were not treated according to the guidelines. The compliance for empirical treatments was 16.3%\u201359.1% and 7.8%\u201330.1% in retrospective and prospective periods, respectively. During the prospective period, a total of 603 recommendations were made by CP, and 578 (95.9%) were accepted and implemented. In the prospective period, treatment duration was shortened, inappropriate fluoroquinolone use was decreased, the switch to oral treatment was increased, and the number of potential drug\u2013drug interactions was decreased (p &lt; 0.001). Compliance with guidelines is essential to be improved to reduce mortality, shorten the length of stay, determine the appropriate antimicrobial duration, and reduce the use of fluoroquinolones and broad-spectrum antibiotics unless necessary. CP intervention contributes to the rational selection of antimicrobials, limiting drug\u2013drug interactions, avoiding toxicities, and compliance with guidelines.<\/jats:p>","DOI":"10.1177\/10815589241232366","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T04:23:45Z","timestamp":1707366225000},"page":"349-358","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Compliance with guideline recommendations in the management of patients with hospitalized community-acquired pneumonia"],"prefix":"10.1177","volume":"72","author":[{"given":"Pinar","family":"Bakir Ekinci","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Kara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulcin","family":"Telli Dizman","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sefa","family":"Metin","sequence":"additional","affiliation":[{"name":"Department of the Clinical Trials, Turkish Medicines and Medical Devices Agency, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Cagkan","family":"Inkaya","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kutay","family":"Demirkan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutfi","family":"Coplu","sequence":"additional","affiliation":[{"name":"Department of Chest Diseases, Hacettepe University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhat","family":"Unal","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03937.x"},{"key":"e_1_3_2_3_2","unstructured":"World Health Organization. The top 10 causes of death. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death (2022 accessed 18 January 2022)."},{"issue":"1","key":"e_1_3_2_4_2","first-page":"15","article-title":"Hastaneye yat\u0131\u015f gerektiren toplum k\u00f6kenli pn\u00f6moni olgular\u0131nda mortalite oran\u0131 ve etkileyen fakt\u00f6rler","volume":"4","author":"Kuluozturk M","year":"2021","unstructured":"Kuluozturk M, Eser G, Agaoglu G, et al. Hastaneye yat\u0131\u015f gerektiren toplum k\u00f6kenli pn\u00f6moni olgular\u0131nda mortalite oran\u0131 ve etkileyen fakt\u00f6rler. T\u0131p Fak\u00fcltesi Klinikleri Dergisi 2021; 4(1): 15\u201321.","journal-title":"T\u0131p Fak\u00fcltesi Klinikleri Dergisi"},{"issue":"6","key":"e_1_3_2_5_2","first-page":"1","article-title":"Demographics, guidelines, and clinical experience in severe community-acquired pneumonia","volume":"12","author":"Rello J","year":"2008","unstructured":"Rello J. Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Crit Care 2008; 12(6): 1\u20139.","journal-title":"Crit Care"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00580-017-2443-1"},{"key":"e_1_3_2_7_2","unstructured":"Sayiner A Azap A Yalci A et al. T\u00fcrk Toraks Derne\u011fi eri\u015fkinlerde toplumda geli\u015fen pn\u00f6moniler tan\u0131 ve tedavi uzla\u015f\u0131 raporu 2021."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0030UP"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03602.x"},{"key":"e_1_3_2_11_2","first-page":"1","article-title":"T\u00fcrk Toraks Derne\u011fi eri\u015fkinlerde toplumda geli\u015fen pn\u00f6moni tan\u0131 ve tedavi uzla\u015f\u0131 raporu","volume":"10","author":"Ozlu T","year":"2009","unstructured":"Ozlu T, Bulbul Y, Alatas F, et al. T\u00fcrk Toraks Derne\u011fi eri\u015fkinlerde toplumda geli\u015fen pn\u00f6moni tan\u0131 ve tedavi uzla\u015f\u0131 raporu. T\u00fcrk Toraks Dergisi 2009; 10: 1\u201316.","journal-title":"T\u00fcrk Toraks Dergisi"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e32835d0a8f"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0080-z"},{"issue":"5","key":"e_1_3_2_14_2","first-page":"406","article-title":"Clinical pharmacist interventions associated with appropriateness and length of inpatient antimicrobial therapy for pneumonia","volume":"8","author":"Curtiss FR","year":"2002","unstructured":"Curtiss FR. Clinical pharmacist interventions associated with appropriateness and length of inpatient antimicrobial therapy for pneumonia. J ManagCare Pharm 2002; 8(5): 406.","journal-title":"J ManagCare Pharm"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.6.736"},{"issue":"3","key":"e_1_3_2_16_2","first-page":"107","article-title":"Toplumda geli\u015fen pn\u00f6monili hastalara klinik yakla\u015f\u0131m","volume":"23","author":"Sevinc B","year":"2009","unstructured":"Sevinc B, Akbaba B, Bilgen BA, et al. Toplumda geli\u015fen pn\u00f6monili hastalara klinik yakla\u015f\u0131m. \u0130zmir G\u00f6u\u011f\u00e4s Hastanesi Dergisi 2009; 23(3): 107\u2013116.","journal-title":"\u0130zmir G\u00f6u\u011f\u00e4s Hastanesi Dergisi"},{"key":"e_1_3_2_17_2","first-page":"297","article-title":"Tu\u00e4rk Toraks Derne\u011fi Pn\u00f6moni Rehberi\u2019ne uygun tedavi verilen ve verilmeyen toplum k\u00f6kenli pn\u00f6monilerde ba\u015far\u0131 oranlar\u0131","volume":"49","author":"Gokirmak M","year":"2001","unstructured":"Gokirmak M, Hasanoglu HC, Yildirim Z, et al. Tu\u00e4rk Toraks Derne\u011fi Pn\u00f6moni Rehberi\u2019ne uygun tedavi verilen ve verilmeyen toplum k\u00f6kenli pn\u00f6monilerde ba\u015far\u0131 oranlar\u0131. Tuberk Toraks 2001; 49: 297\u2013311.","journal-title":"Tuberk Toraks"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200411-1444OC"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00163407"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.6.682"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092607"},{"key":"e_1_3_2_22_2","volume-title":"The sanford guide to antimicrobial therapy","author":"Gilbert DN","year":"2020","unstructured":"Gilbert DN, Chambers HF, Saag MS, et al. The sanford guide to antimicrobial therapy. USA: Antimicrobial Therapy, Inc., 2020."},{"key":"e_1_3_2_23_2","first-page":"A144","article-title":"4CPS-220 Clinical pharmacist interventions in hospitalised patients with renal impairment","volume":"25","author":"Papic I","year":"2018","unstructured":"Papic I, Vrca VB, Marinovi\u0107 I, et al. 4CPS-220 Clinical pharmacist interventions in hospitalised patients with renal impairment. Br Med J 2018; 25: A144.","journal-title":"Br Med J"},{"key":"e_1_3_2_24_2","volume-title":"Fluoroquinolones for the treatment of respiratory tract infections: a review of clinical effectiveness, cost-effectiveness, and guidelines","author":"Cowling T","year":"2019","unstructured":"Cowling T, Farrah K. Fluoroquinolones for the treatment of respiratory tract infections: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health, 2019."},{"key":"e_1_3_2_25_2","first-page":"1","article-title":"Guidelines adherence for patients with community acquired pneumonia in a Greek hospital","volume":"16","author":"Triantafyllidis C","year":"2012","unstructured":"Triantafyllidis C, Kapordelis V, Papaetis G et al. Guidelines adherence for patients with community acquired pneumonia in a Greek hospital. Eur Rev Med Pharmacol Sci 2012; 16: 1\u20139.","journal-title":"et al"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac615"},{"issue":"2","key":"e_1_3_2_27_2","first-page":"S27","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell LA","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(2): S27\u2013S72.","journal-title":"et al"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.8"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2118"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.06.028"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3098-5"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-016-1445-3"}],"container-title":["Journal of Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589241232366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10815589241232366","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589241232366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:40:01Z","timestamp":1777459201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10815589241232366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1177\/10815589241232366"],"URL":"https:\/\/doi.org\/10.1177\/10815589241232366","relation":{},"ISSN":["1081-5589","1708-8267"],"issn-type":[{"value":"1081-5589","type":"print"},{"value":"1708-8267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]}}}